Sociedad Quirúrgica S.C. es el único grupo quirúrgico en México que todos sus socios han tenido entrenamiento en los mejores centros académicos de los estados unidos.

Cuatro de sus socios realizaron todo su entrenamiento como cirujanos y sub especialista en los  Estados Unidos, lo que implica que tienen los consejos de sus especialidades en México y en los Estados Unidos de America.

Rodrigo Arrangoiz MS, MD, FACS

Cirugia General – Michigan State University

(https://surgery.msu.edu/faculty/index.php)

Surgical Oncology / Head and Neck Surgery / Endocrine Surgery – Fox Chase Cancer Center (https://www.foxchase.org)

Head and Neck Surgery and Oncology / Endocrine Surgery – IFHNOS/Memorial Sloan Kettering Cancer Center

(http://www.ifhnos.net/global_online_fellowship.html)

Master in Science (Clinical research for health care professionals) – Drexel University

Fernando Cordera MD, FACS

Cirugia General – Mayo Clinic (http://www.mayo.edu)

Surgical Oncology / Head and Neck Surgery / Endocrine Surgery – Fox Chase Cancer Center (https://www.foxchase.org)

Head and Neck Surgery and Oncology  – IFHNOS/Memorial Sloan Kettering Cancer Center

(http://www.ifhnos.net/global_online_fellowship.html)

David Caba MS, MD, MPH

Cirugia General –  Dartmouth (http://gme.dartmouth-hitchcock.org/general_surgery.html)

Surgical Oncology – University of Chicago

(https://surgery.uchicago.edu/specialties/general/csp/oncology)

Manuel Muñoz MD, FACS, FACRS

Cirugia General – Mayo Clinic (http://www.mayo.edu)

Colorectal surgery – Mayo Clinic (http://www.mayo.edu)

Visiten nuestra pagina:

http://www.sociedadquirurgica.com

El manejo del cáncer se debe de realizar de manera multidisciplinaria que consiste en involucrar médicos y especialista de diferentes campos cómo :

– Cirujanos oncólogos

– Médicos oncólogos

– Radiólogos oncólogos (radiación)

– Radiólogos expertos en cáncer

– Nutriólogos expertos en el manejo del paciente con cancer

– Sicólogos / siquiatras expertos en el manejo del paciente con cancer

– Terapeutas de rehabilitación

– Cirujanos pláticos de reconstrucción

– Enfermeras expertas en el manejo del linfedema

– Terapeutas del lenguaje y deglución

¿Porque la parte quirúrgica del manejo multidisciplinario del cáncer debe ser tratado por un cirujano oncólogo?

• El entrenamiento del cirujano oncólogo esta enfocado al manejo multidisciplinario del paciente con cáncer.
• Su entrenamiento incluye:
– Rotaciones no quirúrgicas en oncología médica y radioterapia, servicios de patología oncológica y rotaciones clínicas en los servicios de melanoma, mama, cabeza y cuello, y cirugía torácica.
– Todos los cirujanos oncólogos entrenados en los programas acreditados por la Sociedad de Cirugía Oncológica (Society of Surgial Oncology – que son muy pocos) participan en programas de investigación clínica de oncología quirúrgica, que puede incluir ciencias básicas e investigación clínica.

• Los cirujanos oncólogos entrenados en los programas de la Sociedad de Cirugía Oncológica (Society of Surgial Oncology) diariamente tienen conferencias multidisciplinares específicas del sitio del tumor, conferencias preoperatorios semanales, clubes de revistas multidisciplinarias, y conferencias de actualidades de oncología:
– Además de recibir entrenamiento formal en cirugía de cáncer, los cirujanos oncólogos están expuestos a la biología del tumor, la bioestadística, diseño de la investigación y la metodología.
– Los servicios por donde rotan incluyen el servicio de tumores gastrointestinales (esófago, estomago, intestino delgado, y colon y recto), hepatopancreatobiliar, tórax, oncología ginecológica, melanoma, sarcoma, mama, y cabeza y cuello.

• Los cirujanos entrenados en estos programas pueden realizar procedimientos utilizando técnicas mínimamente invasivas que incluyen:
– Laparoscópica de una sola incisión (SILS), robótica y la cirugía toracoscópica asistida por video.

http://www.surgonc.org

Nuestro grupo tiene tres cirujanos oncólogos entrenados en los mejores centros académicos de los Estados Unidos de America.

Visite nuestra pagina:

http://www.sociedadquirurgica.com

El manejo del cáncer se debe de realizar de manera multidisciplinaria que consiste en involucrar médicos y especialista de diferentes campos cómo :

– Cirujanos oncólogos

– Médicos oncólogos

– Radiólogos oncólogos (radiación)

– Radiólogos expertos en cáncer

– Nutriólogos expertos en el manejo del paciente con cancer

– Sicólogos / siquiatras expertos en el manejo del paciente con cancer

– Terapeutas de rehabilitación

– Cirujanos pláticos de reconstrucción

– Enfermeras expertas en el manejo del linfedema

– Terapeutas del lenguaje y deglución

¿Porque la parte quirúrgica del manejo multidisciplinario del cáncer debe ser tratado por un cirujano oncólogo?

• El entrenamiento del cirujano oncólogo esta enfocado al manejo multidisciplinario del paciente con cáncer.
• Su entrenamiento incluye:
– Rotaciones no quirúrgicas en oncología médica y radioterapia, servicios de patología oncológica y rotaciones clínicas en los servicios de melanoma, mama, cabeza y cuello, y cirugía torácica.
– Todos los cirujanos oncólogos entrenados en los programas acreditados por la Sociedad de Cirugía Oncológica (Society of Surgial Oncology – que son muy pocos) participan en programas de investigación clínica de oncología quirúrgica, que puede incluir ciencias básicas e investigación clínica.

• Los cirujanos oncólogos entrenados en los programas de la Sociedad de Cirugía Oncológica (Society of Surgial Oncology) diariamente tienen conferencias multidisciplinares específicas del sitio del tumor, conferencias preoperatorios semanales, clubes de revistas multidisciplinarias, y conferencias de actualidades de oncología:
– Además de recibir entrenamiento formal en cirugía de cáncer, los cirujanos oncólogos están expuestos a la biología del tumor, la bioestadística, diseño de la investigación y la metodología.
– Los servicios por donde rotan incluyen el servicio de tumores gastrointestinales (esófago, estomago, intestino delgado, y colon y recto), hepatopancreatobiliar, tórax, oncología ginecológica, melanoma, sarcoma, mama, y cabeza y cuello.

• Los cirujanos entrenados en estos programas pueden realizar procedimientos utilizando técnicas mínimamente invasivas que incluyen:
– Laparoscópica de una sola incisión (SILS), robótica y la cirugía toracoscópica asistida por video.

http://www.surgonc.org

Nuestro grupo tiene tres cirujanos oncólogos entrenados en los mejores centros académicos de los Estados Unidos de America.

Visite nuestra pagina:

http://www.sociedadquirurgica.com

Sociedad Quirúrgica S.C. es el único grupo quirúrgico en México que todos sus socios han tenido entrenamiento en los mejores centros académicos de los estados unidos.

Cuatro de sus socios realizaron todo su entrenamiento como cirujanos y sub especialista en los  Estados Unidos, lo que implica que tienen los consejos de sus especialidades en México y en los Estados Unidos de America.

Rodrigo Arrangoiz MS, MD, FACS

Cirugia General – Michigan State University

(https://surgery.msu.edu/faculty/index.php)

Surgical Oncology / Head and Neck Surgery / Endocrine Surgery – Fox Chase Cancer Center (https://www.foxchase.org)

Head and Neck Surgery and Oncology / Endocrine Surgery – IFHNOS/Memorial Sloan Kettering Cancer Center

(http://www.ifhnos.net/global_online_fellowship.html)

Master in Science (Clinical research for health care professionals) – Drexel University

Fernando Cordera MD, FACS

Cirugia General – Mayo Clinic (http://www.mayo.edu)

Surgical Oncology / Head and Neck Surgery / Endocrine Surgery – Fox Chase Cancer Center (https://www.foxchase.org)

Head and Neck Surgery and Oncology  – IFHNOS/Memorial Sloan Kettering Cancer Center

(http://www.ifhnos.net/global_online_fellowship.html)

David Caba MS, MD, MPH

Cirugia General –  Dartmouth (http://gme.dartmouth-hitchcock.org/general_surgery.html)

Surgical Oncology – University of Chicago

(https://surgery.uchicago.edu/specialties/general/csp/oncology)

Manuel Muñoz MD, FACS, FACRS

Cirugia General – Mayo Clinic (http://www.mayo.edu)

Colorectal surgery – Mayo Clinic (http://www.mayo.edu)

Visiten nuestra pagina:

http://www.sociedadquirurgica.com

Pleomorphic adenoma is a benign salivary gland tumor that exhibits wide cytomorphologic and architectural diversity.

The tumor has the following three components:

• An epithelial cell component

• A myoepithelial cell component

• A stromal (mesenchymal) component

Identification of these three components, which may vary quantitatively from one tumor to another, is essential to the recognition of pleomorphic adenoma.

This tumor is also referred to as a benign mixed tumor.

Epidemiology

Pleomorphic adenoma is the most common salivary gland tumor in both children and adults.

In most series in the literature, it represents approximately 45% to 75% of all salivary gland neoplasms.

The annual incidence is approximately 2.0 to 3.5 cases per 100,000 population.

Pleomorphic adenoma occurs in individuals of all ages. However, it is most common in the third to sixth decades of life.

The average age at presentation is between 43 and 46 years.

Pleomorphic adenoma is seen more often in females than in males (2:1 ratio).

Etiology

Although the etiology of pleomorphic adenoma is unknown, the incidence of this tumor has been found to increase 15 to 20 years after exposure to radiation.

One study suggests that the simian virus (SV40) may play a causative role in the development of pleomorphic adenoma.

Location

Among the major salivary glands (parotid gland, submandibular gland, and sublingual gland), the tail of the superficial lobe of the parotid salivary gland is the most common site of occurrence for pleomorphic adenoma (70% to 80% of cases), although this lesion can occur in any parotid location.

The tumor is less commonly seen in the submandibular salivary gland (10%) and is seldom encountered in the sublingual gland (1%).

With regard to the minor salivary glands (5% to 10% of cases):

• The palate (specifically, the junction of the soft and hard palates) and the lip are the most common sites for pleomorphic adenoma.
• Other sites of minor salivary gland involvement include the nose, the paranasal sinuses, and the larynx.

Rare or unusual sites of occurrence include ectopic salivary gland tissues (eg, in the mandible, neck lymph nodes, or axilla). A case has been reported of a pleomorphic adenoma presenting as a midline nodule in the isthmus of the thyroid in a 66-year-old man.

Multiple tumors are unusual (1:40,000), but metachronous and synchronous tumors do occur.

Synchronous occurrence of pleomorphic adenoma and Warthin tumor (the second most common benign salivary gland tumor) has been reported

Clinical Features 

Pleomorphic adenoma usually presents as a slow-growing, painless mass, which may be present for many years. Symptoms and signs depend on the location.

When the tumor occurs in the parotid gland, signs of facial nerve weakness are seldom encountered; however, if the tumor is large and has been neglected, facial nerve weakness is likely to arise as the result of malignant change.

Pleomorphic adenoma in the deep lobe of the parotid gland may present as an oral retrotonsillar mass or parapharyngeal space tumor; indeed, tumors arising at this site are the source of the most common parapharyngeal space tumors.

Rapid enlargement of a tumor nodule should raise concern about the development of malignant change.

Patients with minor salivary gland tumors may present with a variety of symptoms, depending on the site of the tumor; such symptoms include dysphagia, dyspnea, hoarseness, difficulty in chewing, and epistaxis.

Macroscopic Characteristics

On gross examination, a pleomorphic adenoma is a single firm, mobile, well-circumscribed mass.

Its color may vary from whitish-tan to gray to bluish, and its size may range from a few millimeters to quite large or even giant.

Pleomorphic adenomas are irregularly shaped and have a bosselated surface.

 

Degenerative and cystic changes may be seen on sectioning.

It is not unusual to observe evidence of focal or massive infarction.

Recurrent tumors characteristically tend to present as multiple nodules of variable size.

Rodrigo Arrangoiz MS, MD, FACS

Cirugía General y Gastrointestinal
Michigan State University
Cirugía Oncológica

Fox Chase Cancer Center

Tumores de Cabeza y Cuello / Cirugía Endocrina

Fox Chase Cancer Center

Tumores de Cabeza y Cuello / Cirugía Endocrina

IFHNOS / Memorial Sloan Kettering Cancer Center

Maestría en Ciencias de Investigación
Drexel University
Certificado por el Colegio Americano de Cirugía

Fellow del Colegio Americano de Cirugía

Fellow de la Sociedad de Cirugia Oncológica

Sociedad Quirúrgica S.C.
Hospital ABC Santa Fé
Av. Carlos Graef Fernández #154

Consultorio 515
Col. Tlaxala, Delg. Cuajimalpa
México, D.F. 05300
Tel: 1103 – 1600 Ext 4515 a la 4517
Fax:1664 – 7164

 

rodrigo.arrangoiz@gmail.com

www.sociedadquirurgica.com

www.hiperparatiroidismo.info

A. The maxillary artery supplies the deep structures of the face.

1. It branches from the external carotid artery just deep to the neck of the mandible.

B. Structure:

1. The maxillary artery, the larger of the two terminal branches of the external carotid artery:
– Arises behind the neck of the mandible, and is at first imbedded in the substance of the parotid gland.

2. It passes forward between the ramus of the mandible and the sphenomandibular ligament, and then runs, either superficial or deep to the lateral pterygoid muscle, to the pterygopalatine fossa.

3. It supplies the deep structures of the face.

4. May be divided into:
– Mandibular portion (first part / bone portion)
– Pterygoid portion (second part / muscular portion)
– Pterygopalatine portions (third part).

C. First portion:

1. The first or mandibular portion (or bony portion) passes horizontally forward, between the neck of the mandible and the sphenomandibular ligament:
– Where it lies parallel to and a little below the auriculotemporal nerve.

2. It crosses the inferior alveolar nerve, and runs along the lower border of the lateral pterygoid muscle.

3. Branches include:
– Deep auricular artery
– Anterior tympanic artery
– Middle meningeal artery
– Inferior alveolar artery: which gives off its mylohyoid branch just prior to entering the mandibular foramen
– Accessory meningeal artery

D. Second Portion:

1. The second or pterygoid portion (or muscular portion) runs obliquely forward and upward under cover of the ramus of the mandible and insertion of the temporalis muscle:
– On the superficial (very infrequently on the deep) surface of the lateral pterygoid muscle.
– It then passes between the two heads of origin of this muscle and enters the pterygopalatine fossa.

2. Branches include:
– Masseteric artery
– Pterygoid branches
– Deep temporal arteries
= Anterior and posterior
– Buccal (buccinator) artery

E. Third Portion:

1. The third or pterygopalatine portion lies in the pterygopalatine fossa in relation with the pterygopalatine ganglion.

2. This is considered the terminal branch of the maxillary artery.

3. Branches include:
– Sphenopalatine artery:  also known as the nasopalatine artery which is the terminal branch of the maxillary artery
– Descending palatine artery:
= Greater palatine artery
= Lesser palatine artery
– Infraorbital artery
– Posterior superior alveolar artery
– Artery of pterygoid canal
-Pharyngeal artery
– Middle superior alveolar artery (could be a branch of the infraorbital artery)
– Anterior superior alveolar arteries (could be a branch of the infraorbital artery)

The international After Mapping of the Axilla: Radiotherapy Or Surgery (AMAROS) study randomized 1,425 sentinel lymph node–positive patients to completion ALND or nodal field irradiation without ALND.

• Nodal radiotherapy included axillary, supraclavicular, and low-neck fields.
• There was no statistically significant difference in:
  • Disease-free or overall survival between the treatment arms.
• Axillary radiotherapy was shown to have lower morbidity than ALND, with lower complication rates:
  • Specifically lower rates of lymphedema.
• The 10-year overall survival with extensive nodal radiotherapy was 83% compared with 82% with ALND, and this difference was not statistically significant.
• Axillary recurrence was observed in four of the 744 patients (< 1%) in the ALND group and seven of the 681 patients (1%) in the radiotherapy group, which was also not statistically significantly different.

There have been no randomized trials comparing radiotherapy with SLNB alone.

• The axillary recurrence rate was 1% at 6 years in patients with positive sentinel nodes who received axillary radiation in the AMAROS trial.
  • This is comparable to the axillary recurrence rate of less than 2% at 10 years in the patients randomized to the sentinel lymph node–only arm of ACOSOG Z0011.
  • If the patients and axillary recurrence rates were similar with and without radiation, the utility of nodal radiation for patients with one to two positive sentinel lymph nodes is questionable.

Click to access a8c039c6e049d0c696bb936662de04c16bf1.pdf

Click to access malignant-salivary-gland-neoplasms-literature-review.pdf

The current indications for a segmental mandibulectomy include:

(1) Gross invasion by oral cancer;

(2) Invasion of inferior alveolar nerve or inferior alveolar canal by a tumor;

(3) Massive soft tissue disease adjacent to the mandible;

(4) A primary malignant tumor of the mandible;

(5) A tumor that has metastasized to the mandible.